SCHEMBL17959014

SCHEMBL17959014

O=C(NO)c1ccc2c(c1)CN(Cc1ccccc1)CCCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 11/20 0.57
▸ HDAC1 Q13547 10/20 0.57
▸ ACHE P22303 1/20 0.55
▸ HDAC4 P56524 3/20 0.54
▸ KCNH2 Q12809 1/20 0.54
▸ HDAC8 Q9BY41 3/20 0.50
▸ HDAC10 Q969S8 3/20 0.50
▸ HDAC3 O15379 2/20 0.50
▸ HDAC7 Q8WUI4 2/20 0.50
▸ HDAC2 Q92769 2/20 0.50
▸ HDAC11 Q96DB2 2/20 0.50
▸ HDAC9 Q9UKV0 2/20 0.50
▸ HDAC5 Q9UQL6 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ PKM P14618 2/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17959056 0.91 HDAC6 (0.57) HDAC6HDAC1ACHEHDAC4KCNH2
SCHEMBL20928509 0.84 HDAC1 (0.56) HDAC6HDAC1ACHEHDAC4KCNH2
SCHEMBL17959000 0.83 HDAC1 (0.61) HDAC6HDAC1ACHEHDAC4KCNH2
SCHEMBL14023200 0.82 ALDH1A1 (0.53) HDAC6HDAC1ACHEALDH1A1NPSR1
SCHEMBL17959037 0.81 HDAC6 (0.60) HDAC6HDAC1HDAC4HDAC8HDAC10
SCHEMBL17959067 0.81 HDAC6 (0.47) HDAC6HDAC1ALDH1A1PKMHPGD
SCHEMBL17957505 0.80 HDAC1 (0.56) HDAC6HDAC1HDAC4HDAC8HDAC10
SCHEMBL1264338 0.79 HDAC6 (0.65) HDAC6HDAC1HDAC4KCNH2HDAC8
SCHEMBL17959030 0.78 GPR142 (0.58) HDAC6PKMRAB9ANPC1
SCHEMBL17959025 0.77 HDAC6 (0.50) HDAC6HDAC1ALDH1A1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-22 — — US claimed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO claimed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US claimed
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2025-05-20 — — US disclosed
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2023-11-09 — — US disclosed
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO HEALTH, INC. (US) 2023-07-18 — — US disclosed
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS VALO HEALTH, INC. 2021-07-08 — — US disclosed
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors VALO EARLY DISCOVERY, INC. (US) 2020-12-22 — — US disclosed
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2019-11-14 — — US disclosed
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-10 — — US disclosed
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-28 — — US disclosed
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors FORMA THERAPEUTICS, INC. (US) 2019-01-22 — — US disclosed
WO-2016126726-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-08-11 — — WO disclosed
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, LLC 2016-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357216-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-10870645-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-10407418-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-20160221997-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-10183934-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-12304904-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-20190092762-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-11702412-B2 Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-20190345149-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885
US-20210206755-A1 BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS HDAC1, HDAC2, HDAC4 HDAC6 7/4885HDAC1 1/4885ACHE 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback